Artivion (NYSE:AORT) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Artivion (NYSE:AORT) announced its earnings results on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04, Yahoo Finance reports. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The company had revenue of $97.43 million for the quarter, compared to analyst estimates of $92.30 million. During the same quarter in the previous year, the company earned $0.02 earnings per share. Artivion updated its FY 2024 guidance to EPS.

Artivion Stock Down 1.9 %

Shares of Artivion stock traded down $0.44 during trading on Wednesday, hitting $23.33. 58,655 shares of the stock were exchanged, compared to its average volume of 219,342. The stock has a market cap of $961.20 million, a price-to-earnings ratio of -31.80 and a beta of 1.66. The firm’s 50-day moving average price is $20.48 and its 200 day moving average price is $18.14. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. Artivion has a 12-month low of $12.16 and a 12-month high of $25.51.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Needham & Company LLC raised their target price on Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus upped their target price on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday.

Insider Buying and Selling at Artivion

In other Artivion news, VP Rochelle L. Maney sold 2,315 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.27, for a total transaction of $46,925.05. Following the transaction, the vice president now owns 39,197 shares of the company’s stock, valued at $794,523.19. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Matthew A. Getz sold 5,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $19.94, for a total value of $99,700.00. Following the completion of the sale, the vice president now directly owns 43,536 shares of the company’s stock, valued at $868,107.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Rochelle L. Maney sold 2,315 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.27, for a total value of $46,925.05. Following the transaction, the vice president now directly owns 39,197 shares in the company, valued at approximately $794,523.19. The disclosure for this sale can be found here. Insiders have sold a total of 149,952 shares of company stock worth $2,891,627 over the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.